JP2014501492A5 - - Google Patents

Download PDF

Info

Publication number
JP2014501492A5
JP2014501492A5 JP2013532277A JP2013532277A JP2014501492A5 JP 2014501492 A5 JP2014501492 A5 JP 2014501492A5 JP 2013532277 A JP2013532277 A JP 2013532277A JP 2013532277 A JP2013532277 A JP 2013532277A JP 2014501492 A5 JP2014501492 A5 JP 2014501492A5
Authority
JP
Japan
Prior art keywords
short rna
strand
rna
short
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013532277A
Other languages
English (en)
Japanese (ja)
Other versions
JP5681955B2 (ja
JP2014501492A (ja
Filing date
Publication date
Priority claimed from GBGB1016989.4A external-priority patent/GB201016989D0/en
Priority claimed from GBGB1103745.4A external-priority patent/GB201103745D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/051940 external-priority patent/WO2012046084A2/en
Publication of JP2014501492A publication Critical patent/JP2014501492A/ja
Publication of JP2014501492A5 publication Critical patent/JP2014501492A5/ja
Application granted granted Critical
Publication of JP5681955B2 publication Critical patent/JP5681955B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013532277A 2010-10-08 2011-10-10 短いｒｎａ分子 Expired - Fee Related JP5681955B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1016989.4 2010-10-08
GBGB1016989.4A GB201016989D0 (en) 2010-10-08 2010-10-08 Cell induction
GB1103745.4 2011-03-07
GBGB1103745.4A GB201103745D0 (en) 2011-03-07 2011-03-07 Cell induction
PCT/GB2011/051940 WO2012046084A2 (en) 2010-10-08 2011-10-10 Short rna molecules

Publications (3)

Publication Number Publication Date
JP2014501492A JP2014501492A (ja) 2014-01-23
JP2014501492A5 true JP2014501492A5 (enExample) 2014-11-13
JP5681955B2 JP5681955B2 (ja) 2015-03-11

Family

ID=44860439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013532277A Expired - Fee Related JP5681955B2 (ja) 2010-10-08 2011-10-10 短いｒｎａ分子

Country Status (8)

Country Link
US (6) US8835400B2 (enExample)
EP (2) EP2625272B1 (enExample)
JP (1) JP5681955B2 (enExample)
KR (1) KR20130132795A (enExample)
CN (1) CN103314108B (enExample)
AU (1) AU2011311344B2 (enExample)
CA (1) CA2817191A1 (enExample)
WO (2) WO2012046085A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817191A1 (en) * 2010-10-08 2012-04-12 Pal Saetrom Short rna molecules
DK2880167T3 (en) 2012-07-31 2018-07-30 Univ Texas METHODS AND COMPOSITIONS FOR IN VIVO-INDUCTION OF PANCREAS BETA CELL CREATION
EP3985118A1 (en) 2013-11-22 2022-04-20 MiNA Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
WO2015162422A1 (en) * 2014-04-22 2015-10-29 Mina Therapeutics Limited Sarna compositions and methods of use
JP2018512876A (ja) * 2015-04-22 2018-05-24 ミナ セラピューティクス リミテッド ｓａＲＮＡ組成物および使用方法
CN106480028B (zh) * 2016-10-12 2019-04-05 上海市第七人民医院 TPO基因的saRNA分子及其应用
AU2018290250B2 (en) * 2017-06-21 2025-05-22 Timothy A. Bertram Immunoprivileged bioactive renal cells for the treatment of kidney disease
KR102007457B1 (ko) 2017-06-30 2019-08-05 동국대학교 산학협력단 Cas9 단백질, 가이드 RNA 및 양친매성 펩타이드를 포함하는 나노복합체 및 이의 용도
AU2018314236B2 (en) * 2017-08-11 2025-02-06 Apterna Limited RNA aptamers against transferrin receptor (TfR)
AU2018330494A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited HNF4a saRNA compositions and methods of use
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
AU2019252204A1 (en) * 2018-04-10 2020-11-26 Ractigen Therapeutics Novel small activating RNA
CN112840025A (zh) * 2018-05-08 2021-05-25 迈阿密大学 用于将治疗性核酸递送到组织的材料方法
WO2019239144A1 (en) 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
JP2022545101A (ja) 2019-08-19 2022-10-25 ミナ セラピューティクス リミテッド オリゴヌクレオチドコンジュゲート組成物および使用方法
EP4329777A1 (en) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US8193330B2 (en) 1999-04-06 2012-06-05 The Regents Of The University Of California Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
CA2404890C (en) 2000-03-30 2013-11-19 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
GB0329449D0 (en) 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
EP1871426B1 (en) * 2005-04-15 2017-06-07 The Regents of The University of California Small activating rna molecules and their use
US8357666B2 (en) 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
JP5066095B2 (ja) 2005-11-17 2012-11-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
WO2008109556A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting telomerase gene expression and uses thereof
EP2126082A1 (en) * 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
PT2164993T (pt) 2007-05-29 2017-01-12 Reid Christopher B Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih
WO2009046397A2 (en) 2007-10-04 2009-04-09 Board Of Regents, The University Of Texas System Modulating gene expression with agrna and gapmers targeting antisense transcripts
CA2710953A1 (en) 2007-12-28 2009-07-09 The Regents Of The University Of California Methods and compositions for increasing gene expression
EP2276838A4 (en) 2008-04-07 2012-02-01 Nupotential Inc RE-PROGRAMMING A CELL BY INDUCING A PLURIPOTENTIC GENE THROUGH RNA INTERFERENCE
WO2009126927A2 (en) 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Methods of generating insulin-producing cells
CN102264898B (zh) 2008-10-23 2013-10-16 国立大学法人东京大学 微小rna的功能抑制方法
NZ592821A (en) * 2008-11-13 2012-06-29 Baylor Res Inst Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo
WO2010108126A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
EP2432881B1 (en) 2009-05-18 2017-11-15 CuRNA, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
SG177483A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
US8912157B2 (en) * 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
GB201010557D0 (en) 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
US8635602B2 (en) 2010-07-26 2014-01-21 International Business Machines Corporation Verification of information-flow downgraders
CA2817191A1 (en) * 2010-10-08 2012-04-12 Pal Saetrom Short rna molecules

Similar Documents

Publication Publication Date Title
JP2014501492A5 (enExample)
MX359548B (es) Agentes de iarn modificados.
MX342731B (es) Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
WO2014022739A3 (en) Modified rnai agents
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
MY176863A (en) Ibat inhibitors for treatment of metabolic disorders and related conditions
EA200870366A1 (ru) Короткая внутренне сегментированная интерферирующая рнк
EA200802247A1 (ru) Схема дозирования кладрибина для лечения рассеянного склероза
BR112012018116A2 (pt) "hormônios do crescimento com eficácia in vivo prolongada"
JP2014500249A5 (enExample)
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
WO2009029622A3 (en) Antiviral drugs for treatment of arenavirus infection
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
JP2013503110A5 (enExample)
UY32444A (es) Composiciones y procedimientos para terapia extendida con aminopiridinas
JP2015514778A5 (enExample)
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
WO2011038933A3 (en) Anti-hsv antibody
BR112014002173A2 (pt) proteínas purificadas
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MX2011012384A (es) Derivados nitrilo y sus usos y composiciones farmaceuticas.
MX2013003698A (es) Agente preventivo o terapeutico contra la fibrosis.
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
EA201290485A1 (ru) Производные бензамида